These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32589146)

  • 1. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
    Yin G; Zhang C; Jin H
    JMIR Public Health Surveill; 2020 Jul; 6(3):e19538. PubMed ID: 32589146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
    Ader F;
    BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
    Lai CC; Chao CM; Hsueh PR
    J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
    Izcovich A; Siemieniuk RA; Bartoszko JJ; Ge L; Zeraatkar D; Kum E; Qasim A; Khamis AM; Rochwerg B; Agoritsas T; Chu DK; McLeod SL; Mustafa RA; Vandvik P; Brignardello-Petersen R
    BMJ Open; 2022 Mar; 12(3):e048502. PubMed ID: 35236729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the efficacy of remdesivir so different from that of lopinavir-ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review.
    Isidoro Duarte T; Vieira C; Pimentel C; Cascão M; Torre M; Santos-Lima J; Sequeira T; Germano N; Corte-Real R; Bento L
    Anaesthesiol Intensive Ther; 2021; 53(4):363-365. PubMed ID: 35257569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.
    Flisiak R; Zarębska-Michaluk D; Berkan-Kawińska A; Tudrujek-Zdunek M; Rogalska M; Piekarska A; Kozielewicz D; Kłos K; Rorat M; Bolewska B; Szymanek-Pasternak A; Mazur W; Lorenc B; Podlasin R; Sikorska K; Oczko-Grzesik B; Iwaszkiewicz C; Szetela B; Pabjan P; Pawłowska M; Tomasiewicz K; Polańska J; Jaroszewicz J
    Pol Arch Intern Med; 2021 Jan; 131(1):103-110. PubMed ID: 33382547
    [No Abstract]   [Full Text] [Related]  

  • 9. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
    WHO Solidarity Trial Consortium
    Lancet; 2022 May; 399(10339):1941-1953. PubMed ID: 35512728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
    ; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
    N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
    Sheahan TP; Sims AC; Leist SR; Schäfer A; Won J; Brown AJ; Montgomery SA; Hogg A; Babusis D; Clarke MO; Spahn JE; Bauer L; Sellers S; Porter D; Feng JY; Cihlar T; Jordan R; Denison MR; Baric RS
    Nat Commun; 2020 Jan; 11(1):222. PubMed ID: 31924756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
    Alabdalaali MM; Hadi AM
    Arch Razi Inst; 2023 Jun; 78(3):935-941. PubMed ID: 38028857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
    Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
    Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.